Amgen (NASDAQ:AMGN) filed an 8-K on November 11, 2026, disclosing full Phase 3 OASIZ-301 trial results for dazodalibep in patients with Sjogren's disease, presented at the American College of Rheumatology Convergence 2026.

Key Highlights

  • Primary endpoint met by both doses: Both dazodalibep regimens (1,500 mg every four weeks and 3,000 mg every 12 weeks) demonstrated statistically significant reductions in ESSDAI score at Week 48 compared with placebo.
  • 1,500 mg regimen result: The 1,500 mg every four weeks group (n=217) showed a least-squares mean ESSDAI reduction of 5.6 points versus 3.8 points for placebo, a difference of 1.8 points (adjusted p<0.001).
  • 3,000 mg regimen result: The 3,000 mg every 12 weeks group (n=217) showed a reduction of 5.2 points versus 3.8 points for placebo, a difference of 1.4 points (adjusted p=0.010).
  • Early and sustained effect: A treatment effect was observed as early as Week 4 and sustained through Week 48, according to the filing.
  • Patient-reported dryness improved: At Week 48, the 1,500 mg every four weeks regimen showed placebo-adjusted differences of -1.17 points on the ESSPRI dryness domain and -0.93 points on the DASPRI dryness domain (adjusted p<0.001 for both).
  • Study size: OASIZ-301 enrolled 648 patients with moderate-to-severe systemic Sjogren's disease activity (ESSDAI score of 5 or higher), with a mean baseline ESSDAI score of 10.2.
  • No approved therapies exist: According to the filing, there are currently no approved therapies for Sjogren's disease.

OASIZ-301 Data: Dazodalibep's Phase 3 Outcomes in Sjogren's Disease

According to the filing, the OASIZ-301 study was a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of dazodalibep in patients with Sjogren's disease who had moderate-to-severe systemic disease activity, defined as an ESSDAI score of 5 or greater. The study enrolled 648 patients, and the primary endpoint was change from baseline in ESSDAI score at Week 48. Both dosing regimens met this primary endpoint with statistically significant reductions compared with placebo.

The filing notes that key secondary endpoints evaluated dryness, tender and swollen joints, fatigue, and ESSDAI response defined as a decrease of at least 5 points from baseline. Additional analyses presented at ACR Convergence 2026 included responder analyses showing proportions of patients achieving reductions of at least 3, 5, or 7 points on the ESSDAI, as well as domain-level responses covering constitutional, glandular, articular, lymphadenopathy, cutaneous, and biological domains. The filing also reports that mean improvement in total ESSPRI exceeded 1.5 points with both dosing regimens, which the filing describes as "consistent with clinically meaningful improvement." Patients treated with dazodalibep also showed greater increases in stimulated salivary flow compared with placebo.

Regarding safety, the filing states the most common adverse events (occurring at 5% or greater incidence and at a higher rate in dazodalibep-treated patients than placebo) were nasopharyngitis, urinary tract infection, hypertension, and infusion-related reactions, described as "generally mild to moderate in nature." Serious adverse events and discontinuations due to adverse events were reported as balanced across all three treatment groups. The filing states no imbalance in thromboembolic events or opportunistic infections was observed, and malignancy rates were described as "low and comparable across groups." Amgen also disclosed it is conducting two additional studies: OASIZ-303, a Phase 3 trial in patients with high symptom burden and low systemic disease activity, and OASIZ-304, an open-label long-term extension study.

What Was Disclosed

Amgen disclosed full Phase 3 OASIZ-301 results for dazodalibep in Sjogren's disease on November 11, 2026, showing both dosing regimens met the primary ESSDAI endpoint at Week 48, with the 1,500 mg every four weeks regimen also significantly improving patient-reported dryness.